Top 5 Prescription NSAIDs for Dogs in Canada 2026: Meloxicam, Carprofen, Deracoxib, Firocoxib, Robenacoxib - A Veterinarian-Recommended, Evidence-Based Guide

Galliprant (grapiprant) is a market leader thanks to its targeted EP4 receptor mechanism, which differentiates it technically from traditional COX-inhibiting NSAIDs and positions it as an alternative for long-term osteoarthritis management. Its flavored tablet format aids owner compliance, and while it may command a premium price versus generics like carprofen chewables, it provides a distinct pharmacologic option that can be financially justified for patients where receptor-selectivity is preferred.

Metacam is positioned as the market-leading, reference-brand meloxicam oral suspension due to its long record of veterinary clinical use and regulatory approvals; clinics favor it for consistent manufacturing standards and comprehensive pharmacovigilance. While typically priced higher than generics on this list, Metacam’s brand recognition and proven label dosing make it the preferred choice for practices that prioritize predictable supply and documented clinical data over lower-cost alternatives.

Metacam (meloxicam) holds a best-in-class position because of its long track record in dogs, predictable pharmacology and a well-established safety profile for perioperative and short-term postoperative pain control, making it a financially sensible choice for clinics that value reliability. Compared with the other injectables on this list it offers broad clinical familiarity and typically lower monitoring burden than older nonselective options like ketoprofen (Anafen), though it is less COX-2 selective than firocoxib (Previcox) and robenacoxib (Onsior). Its combination of efficacy, availability and often-competitive pricing versus branded COX-2 agents helps explain its widespread veterinary use for prescription injectable NSAID therapy in dogs.

Rimadyl (carprofen) is a long-established oral NSAID with extensive clinical use and brand recognition, often chosen for its predictable analgesic profile and palatable chewable format that helps with owner compliance compared to topical-only approaches. Against topical Surpass it provides systemic control for multi-joint disease, and versus other chewable competitors it frequently competes on price and generic availability, giving it a favorable financial position for clinics managing chronic osteoarthritis. While systemic by nature, Rimadyl’s large safety database can reduce perceived risk for prescribers when compared to newer agents.

Previcox (firocoxib) is a highly COX-2 selective NSAID commonly used for once-daily management of canine osteoarthritis, known for its predictable dosing and favorable long-term safety profile. As a market leader for COX-2–specific therapy, Previcox competes by offering reliable efficacy combined with strong value where generics are available, often undercutting the cost of some branded short-term or perioperative options while maintaining a focused COX-2 benefit.